Hepatitis C virus eradication with direct antiviral agents and liver cancer recurrence: Is the best the enemy of the good?

about

Hepatitis C virus eradication with direct antiviral agents and liver cancer recurrence: Is the best the enemy of the good?

Item

http://www.wikidata.org/entity/Q45327946

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Hepatitis C virus eradication ...... he best the enemy of the good?

@en

Hepatitis C virus eradication ...... he best the enemy of the good?

@nl

type

Item

label

Hepatitis C virus eradication ...... he best the enemy of the good?

@en

Hepatitis C virus eradication ...... he best the enemy of the good?

@nl

prefLabel

Hepatitis C virus eradication ...... he best the enemy of the good?

@en

Hepatitis C virus eradication ...... he best the enemy of the good?

@nl

P1476

Hepatitis C virus eradication ...... he best the enemy of the good?

@en

P2093

Ana Lleo

http://www.w3.org/2001/XMLSchema#string

Massimo Colombo

http://www.w3.org/2001/XMLSchema#string

Savino Bruno

http://www.w3.org/2001/XMLSchema#string

P2860

Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.

Hepatocellular carcinoma: clinical frontiers and perspectives.

Is hepatitis C virus carcinogenic?

Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.

ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.

Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Direct-Acting Antiviral Therapy Restores Immune Tolerance to Patients With Hepatitis C Virus-Induced Cryoglobulinemia Vasculitis.

Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.

Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

P304

1110-1112

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1111/LIV.13479

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

A Lleo

Savino Bruno

Massimo Colombo

P577

2017-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28710819

http://www.w3.org/2001/XMLSchema#string